Company news

Alterity Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4E and Annual Report

August 31, 2017

Prana commences research collaboration with Takeda

July 18, 2017

PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

July 3, 2017

PBT434 presented at 13th International AD/PD Conference

March 30, 2017

Half Year Accounts

February 24, 2017

Business Update

December 23, 2016

S&P DJ Indices Announces March Quarterly Review

November 7, 2016

S&P DJ Indices Announces March Quarterly Rebalance

November 6, 2016

Prana provides regulatory update for PBT2

November 2, 2016

Prana announces $4.8 million R&D refund

October 30, 2016

New Reach2HD data presented at American Neurological Assoc.

October 18, 2016

Prana announces $6.5 million R&D refund

May 9, 2016

FDA Orphan Drug Designation for PBT2 for Huntington Disease

March 30, 2016

Prana to commence Phase 11b trial on PBT2

March 30, 2016

Prana selects lead PD drug candidate for development

March 30, 2016

Prana Provides Analysis of PBT2 Therapeutic Strategy for AD

March 30, 2016

Investment by Quintiles, Placement of 225 million Shares

March 30, 2016

Appendix 4E for the Year Ended 30 June 2010

March 30, 2016

Quintiles Makes Second Investment in Prana

March 30, 2016

Prana`s PBT2 Phase II trial receives funding from ADDF

March 30, 2016

Prana Raises A$6.19 million in a Private Placement

March 30, 2016

Prana accelerates PBT2 commercial development

March 30, 2016

PBT2 - Directly Restores Neurons Critical to Cognition

March 30, 2016

Prana`s PBT2 Directly Restores Neurons Critical to Cognition

March 30, 2016

Prana Receives Michael J. Fox Foundation Grant

March 30, 2016

Prana Announces At-the-Market Issuance Program

March 30, 2016

PBT2 reverses the loss of synaptic activity in neurons

March 30, 2016

Landmark Publication Endorses Prana`s Strategy

March 30, 2016

Key Patent for Parkinson`s Drug PBT434 Secured in USA

March 30, 2016

Australian Government funds study into benefits of PBT2

March 30, 2016

Significant Promise in the Fight Against Alzheimers Disease

March 30, 2016

Prana Receives Recommendation to Proceed with Clinical Trial

March 30, 2016

Prana Provides Clinical Trials Update

March 30, 2016

Prana Doses First Patient in the IMAGINE Phase II Trial

March 30, 2016

Prana Comments on Neurology Publication Huntington Data

March 30, 2016

First Patient Enrolled in Phase II Huntington Disease Trial

March 30, 2016

Appendix 4E - Preliminary Financial Report

March 30, 2016

Appendix 4C - Quarterly report

March 30, 2016

Pranas PBT434 shows potential as treatment in PD

March 30, 2016

Pranas PBT434 Inhibits PD Protein & Brain Cell Death

March 30, 2016

Pranas PBT2 Reduces Tau Related Cognitive Impairment

March 30, 2016

Prana Provides Huntington Disease Trial Update

March 30, 2016

Prana Provides Clinical Trials Safety and Progress Update

March 30, 2016

Prana Doses 1st Patient in PBT2 Alzheimers Extension Study

March 30, 2016

Prana details PBT2 data on reduced Tau Cognitive Impairment

March 30, 2016

Prana Completes Recruitment in Huntington Trial

March 30, 2016

Prana Completes Recruitment in Alzheimers Trial

March 30, 2016

Prana Completes Phase 2 Huntington Disease Trial with PBT2

March 30, 2016

Prana Announces Successful A$7 milion Capital Raising

March 30, 2016

Prana announces $5.8 million R&D refund

March 30, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 47 decks. Every deck is listed under its year.